Fatigue can be a significant burden for people with idiopathic pulmonary fibrosis (IPF), and tends to worsen as the…
Articles by Joana Carvalho, PhD
Endeavor BioMedicines has raised $62 million in series A funding to support the launch of two Phase 2 trials evaluating…
iBio has received a U.S. patent for its method of increasing the amount and quality of endostatin-derived peptides generated…
GLPG1205, an investigational therapy by Galapagos, was found to be safe and well tolerated, with an ability…
A first patient has been enrolled in a proof-of-concept Phase 2 trial of C21 (VP01), Vicore Pharma’s investigational…
People with idiopathic pulmonary fibrosis (IPF) who have three or more abnormally large lymph nodes in the area…
Patients diagnosed with idiopathic pulmonary fibrosis (IPF) in more recent years appear to have a lower risk of mortality…
The Centers for Medicare and Medicaid Services (CMS) has given the status of Advanced Diagnostic Laboratory Test (ADLT) to…
NXP004, Nuformix’s potential anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF), led to a dose-dependent reduction in the…
Ofev (nintedanib) helped more patients with progressive fibrosing interstitial lung diseases (ILDs) avoid a decline in lung…